362 related articles for article (PubMed ID: 8099806)
21. Cytotoxic synergism between trimetrexate and etoposide. Evidence that trimetrexate potentiates etoposide-induced protein-associated DNA strand breaks in L1210 leukemia cells through alterations in intracellular ATP concentrations.
Fry DW
Biochem Pharmacol; 1990 Nov; 40(9):1981-8. PubMed ID: 2146963
[TBL] [Abstract][Full Text] [Related]
22. L1210 cells cultivated under the selection pressure of doxorubicin or vincristine express common mechanisms of multidrug resistance based on the overexpression of P-glycoprotein.
Bohácová V; Sulová Z; Dovinová I; Poláková E; Barancík M; Uhrík B; Orlický J; Breier A
Toxicol In Vitro; 2006 Dec; 20(8):1560-8. PubMed ID: 16962737
[TBL] [Abstract][Full Text] [Related]
23. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
24. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
25. Induced multidrug resistance in murine leukemia L1210 and associated changes in a surface-membrane glycoprotein.
Volm M; Bak M; Efferth T; Mattern J
J Cancer Res Clin Oncol; 1989; 115(1):17-24. PubMed ID: 2563999
[TBL] [Abstract][Full Text] [Related]
26. In vitro cytotoxicity of S16020-2, a new olivacine derivative.
Léonce S; Perez V; Casabianca-Pignede MR; Anstett M; Bisagni E; Pierré A; Atassi G
Invest New Drugs; 1996; 14(2):169-80. PubMed ID: 8913838
[TBL] [Abstract][Full Text] [Related]
27. Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance.
Roberts DW; Foglesong PD; Parganas E; Wiggins L
Cancer Chemother Pharmacol; 1989; 23(3):161-8. PubMed ID: 2538249
[TBL] [Abstract][Full Text] [Related]
28. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
[TBL] [Abstract][Full Text] [Related]
29. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA
Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033
[TBL] [Abstract][Full Text] [Related]
30. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
31. Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A.
Vichi PJ; Tritton TR
Cancer Res; 1993 Nov; 53(21):5237-43. PubMed ID: 8106144
[TBL] [Abstract][Full Text] [Related]
32. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
34. Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein.
Yin MB; Guo B; Voigt W; Vanhoefer U; Gibbs JF; Skenderis BS; Frank C; Wrzosek C; Rustum YM
Biochim Biophys Acta; 1998 Mar; 1401(3):265-76. PubMed ID: 9540817
[TBL] [Abstract][Full Text] [Related]
35. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
[TBL] [Abstract][Full Text] [Related]
36. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
[TBL] [Abstract][Full Text] [Related]
37. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
Barret JM; Calsou P; Larsen AK; Salles B
Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
[TBL] [Abstract][Full Text] [Related]
38. Determination of DNA topoisomerase II activity from L1210 cells--a target for screening antitumor agents.
Wang LG; Liu XM; Ji XJ
Zhongguo Yao Li Xue Bao; 1991 Mar; 12(2):108-14. PubMed ID: 1663690
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection.
Chen KG; Jaffrézou JP; Fleming WH; Durán GE; Sikic BI
Cancer Res; 1994 Sep; 54(18):4980-7. PubMed ID: 7915196
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
Rappa G; Lorico A; Liu MC; Kruh GD; Cory AH; Cory JG; Sartorelli AC
Biochem Pharmacol; 1997 Sep; 54(6):649-55. PubMed ID: 9310341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]